Loading…
BioAtla, Inc. is projected to rise to $4.08 by 2027, a +9% move from its current price of $3.73. BCAB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.54 | $3.73 | $3.94 | +0.04% |
| May 30 | $3.46 | $3.73 | $4.03 | +0.07% |
| May 31 | $3.40 | $3.73 | $4.10 | +0.11% |
| Jun 1 | $3.36 | $3.74 | $4.16 | +0.14% |
| Jun 2 | $3.32 | $3.74 | $4.21 | +0.18% |
| Jun 3 | $3.28 | $3.74 | $4.26 | +0.21% |
| Jun 4 | $3.25 | $3.74 | $4.31 | +0.25% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.25 | $3.74 | $4.31 | +0.25% |
| Week 2 | $3.07 | $3.75 | $4.58 | +0.50% |
| Week 3 | $2.94 | $3.76 | $4.80 | +0.75% |
| Week 4 | $2.84 | $3.77 | $5.00 | +1.01% |
| Week 5 | $2.75 | $3.78 | $5.18 | +1.26% |
| Week 6 | $2.68 | $3.79 | $5.35 | +1.51% |
| Week 7 | $2.61 | $3.80 | $5.51 | +1.77% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BioAtla, Inc. is a clinical-stage biopharmaceutical company in Healthcare that develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
Its lead clinical-stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
BioAtla, Inc. (BCAB) is a clinical-stage biopharmaceutical company in Healthcare. The current price is $3.69, with a market cap of $6.11M and a rank of 5290.
The forecasted price path through 2026-2050 shows year-by-year expectations. In 2026 the avg price is $3.69 (min $3.62, max $5.19); in 2027 the avg is $4.06; in 2028 $3.63; in 2029 $3.04; in 2030 $3.51; in 2031 $3.35; in 2032 $4.05; in 2033 $5.24; in 2034 $4.85; in 2035 $4.46; in 2040 $6.54; and in 2050 $7.72. The forecast shows ROIs of 0, 9.9, -1.7, -17.5, -4.7, -9.3, 9.7, 41.9, 31.3, 21, 77.2, and 109.2 across these years, with sentiment shifting from Neutral to Bullish in later years.
A major floor 41.8% below — a decisive break under it would weaken the trend.
The nearest floor, 3.1% below — buyers have tended to step in here.
The nearest ceiling, 56.6% above — a clean break opens room to run.
A major ceiling 373.2% above — clearing it would confirm fresh momentum.
Key BCAB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BCAB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.71 | Buy | $3.80 | Sell |
| MA 10 | $3.94 | Sell | $3.93 | Sell |
| MA 20 | $4.19 | Sell | $4.23 | Sell |
| MA 50 | $5.36 | Sell | $6.01 | Sell |
| MA 100 | $8.93 | Sell | $10.61 | Sell |
| MA 200 | $21.81 | Sell | $18.24 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 37.11 | Neutral |
| Stoch RSI (14) | 31.16 | Neutral |
| CCI (20) | -98.24 | Neutral |
| Williams %R (14) | -90.61 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | -22.93 | Sell |
| Bollinger %B (20,2) | 0.18 | Neutral |
| Stochastic %K (14) | 9.39 | Buy |
| TRIX (15) | -1.36 | Sell |
| Awesome (5,34) | -0.74 | Sell |
| Ultimate (7,14,28) | 30.51 | Neutral |
| Momentum (10) | -0.81 | Sell |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 3.67 | Buy |
| ADX (14) | 24.43 | Sell |
| ATR (14) | 0.23 | Info |
The 30-day technical picture is NEUTRAL. RSI (14) is 30. The 50-day simple moving average is $5.56 and the 200-day simple moving average is $21.96. Support sits at $3.62 and resistance at $5.84. The 30-day price range spans $2.58 to $5.28.
Overall, near-term momentum is subdued, with the present price sitting near the lower end of the implied range and a nearby resistance level just above the current price.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.62 | $3.73 | $5.25 | 0% | Neutral | |
| $2.94 | $4.08 | $6.14 | +9% | Neutral | |
| $2.51 | $3.70 | $5.91 | -1% | Neutral | |
| $2.00 | $3.10 | $5.19 | -17% | Bearish | |
| $2.17 | $3.53 | $6.15 | -5% | Neutral | |
| $2.02 | $3.43 | $6.18 | -8% | Neutral | |
| $2.31 | $4.10 | $7.62 | +10% | Neutral | |
| $2.83 | $5.21 | $9.95 | +40% | Bullish | |
| $2.57 | $4.94 | $9.66 | +32% | Bullish | |
| $2.29 | $4.56 | $9.13 | +22% | Bullish | |
| $3.00 | $6.67 | $14.67 | +79% | Bullish | |
| $3.53 | $7.85 | $18.05 | +110% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.62 | $3.73 | $4.41 | +0.00% |
| June 2026 | $3.16 | $3.78 | $4.70 | +1.44% |
| July 2026 | $3.16 | $3.85 | $4.91 | +1.84% |
| August 2026 | $2.97 | $3.67 | $4.76 | -4.83% |
| September 2026 | $2.93 | $3.67 | $4.84 | -0.05% |
| October 2026 | $3.12 | $3.94 | $5.27 | +7.45% |
| November 2026 | $3.12 | $3.98 | $5.39 | +1.06% |
| December 2026 | $2.98 | $3.83 | $5.25 | -3.78% |
Click any year to see its month-by-month BCAB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, BCAB is projected to trade between $3.62 and $5.25, averaging $3.73 — a potential gain of 0% from today's $3.73. A consolidation phase looks the most probable path here.
BioAtla, Inc.'s 2027 outlook centres on $4.08, within a $2.94 to $6.14 range. That is up +9% on the projected 2026 average. That marks a +9% change versus current levels. Price action looks broadly range-bound.
By 2028, BCAB could reach as high as $5.91, with a base case around $3.70 and support toward $2.51 — roughly -1% from $3.73. A consolidation phase looks the most probable path here.
Expect BCAB to range from $2.00 to $5.19 through 2029. The $3.10 average target implies a -17% move from current prices. That is -16% versus the projected 2028 average. A cyclical pullback looks likely — prices rarely move in a straight line.
The BCAB price prediction for 2030 points to an average of $3.53 (low $2.17, high $6.15) — a potential decline of -5% on today's $3.73. A consolidation phase looks the most probable path here.
In 2031, BCAB is projected to trade between $2.02 and $6.18, averaging $3.43 — a potential decline of -8% from today's $3.73. That is -3% versus the projected 2030 average. Price action looks broadly range-bound.
BioAtla, Inc.'s 2032 outlook centres on $4.10, within a $2.31 to $7.62 range. That is up +20% on the projected 2031 average. That marks a +10% change versus current levels. A consolidation phase looks the most probable path here.
By 2033, BCAB could reach as high as $9.95, with a base case around $5.21 and support toward $2.83 — roughly +40% from $3.73. Momentum favours further upside here.
Expect BCAB to range from $2.57 to $9.66 through 2034. The $4.94 average target implies a +32% move from current prices. That is -5% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The BCAB price prediction for 2035 points to an average of $4.56 (low $2.29, high $9.13) — a potential gain of +22% on today's $3.73. Momentum favours further upside here.
In 2040, BCAB is projected to trade between $3.00 and $14.67, averaging $6.67 — a potential gain of +79% from today's $3.73. That is up +46% on the projected 2035 average. Buyers look set to stay in control over this stretch.
BioAtla, Inc.'s 2050 outlook centres on $7.85, within a $3.53 to $18.05 range. That is up +18% on the projected 2040 average. That marks a +110% change versus current levels. Momentum favours further upside here.
Investing $1,000 in BCAB today (≈ 268.096515 BCAB) could be worth
$2,103.89
+$1,103.89 (+110%) by 2050 · US Dollar
Based on the average projected BCAB price of $7.85 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BCABwould be worth at today's price.
$1,000 invested in BCAB on May 27, 2025 (≈ 52.49344 BCAB) would be worth
$195.8
-$804.2 (-80.4%) today · 0.20× · US Dollar
Based on a BCAB entry price of $19.05 vs. today's $3.73.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.62 | $1,030.39 | +3.0% |
| 1 month ago | $4.51 | $827.05 | -17.3% |
| 3 months ago | $11.85 | $314.77 | -68.5% |
| 6 months ago | $45.2 | $82.52 | -91.7% |
| 1 year ago | $19.05 | $195.8 | -80.4% |
| All time (5.0y) ago | $2,106.5 | $1.77 | -99.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BCAB forecast.
Our base-case forecast reaches $7.50 around 2050.
Implied market cap at $7.50: $12.43M
The multi-year forecast shows a mixed path with early years exhibiting flatter/mixed pricing and later years turning bullish. In 2030 the avg price is $3.51, with a min of $2.16 and a max of $6.13, and an ROI of -4.7% (Neutral). By 2033 the max reaches $10.00 with an avg of $5.24 and a bullish tilt (ROI 41.9%).
The sequence continues through 2034 (avg $4.85, max $9.49, ROI 31.3%, Bullish) and 2035 (avg $4.46, max $8.94, ROI 21%, Bullish).
Further out, 2040 shows a strong upside path with an avg of $6.54, max $14.38 and ROI of 77.2% (Bullish). By 2050 the forecast extends to an avg of $7.72, max $17.75 and ROI of 109.2% (Bullish). These are estimates, not guarantees, and reflect a path that becomes more favorable in the long run despite earlier volatility and intermittent declines.
Tap a question to reveal the answer.
2030 min $2.16, avg $3.51, max $6.13, ROI -4.7%, sentiment Neutral.
Yes. The 2033 forecast shows a max of $10.00 with an avg of $5.24 and ROI 41.9%, sentiment Bullish.
The long-term forecast shows bullish sentiment in 2033, 2034, 2035, 2040 and 2050 with higher ROIs (e.g., 41.9%, 31.3%, 21%, 77.2%, 109.2%), but earlier years include Neutral or Bearish periods (e.g., 2029: -17.5%, 2028: -1.7%, 2031: -9.3%). These are estimates, not guarantees.
Sentiment: Neutral. RSI(14): 30. SMA50: $5.56. SMA200: $21.96. Support: $3.62. Resistance: $5.84. 30-day range: $2.58 to $5.28.
Current price is $3.69. Market cap is $6.11M. Rank: 5290.
BioAtla, Inc. Community Discussion
0Share your BioAtla, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.